Studies in which we participate include:

Antimicrobial Resistance in sputum Obtained from Patients with CF
Sponsor: CFFoundation
Children’s Hospital and Regional Medical Center
Seattle, Washington

Combination therapy in pulmonary arterial hypertension
Protocol: AC-052-414
Sponsor: ACTELION: http://www.actelion.com
CRO: PAREXEL: http://www.parexel.com/

EAP for Aztreonam Lysine for Inhalation
Protocol: EA-US-205-0111
Sponsor: GILEAD: http://www.gilead.com/
CRO: PAREXEL http://www.parexel.com/

TOPIC: Multi-center, randomized, double-blind, placebo-controlled trial of Pulmozyme withdrawal on exercise tolerance in cystic
fibrosis subjects with severe lung disease
Protocol: Z3877G
Sponsor: GENENTECH: http://www.gene.com/gene/index.jsp
CRO: PPD: http://www.ppdi.com/

SYMBICORT pMDI
Protocol: D589CC00003
Sponsor: AztraZeneca: http://www.astrazeneca.com/
CRO: PAREXEL: http://www.parexel.com/

TRANSAVE: Multi-dose safety and tolerability study of liposomal amikacin for inhalation (Arikace) in cystic fibrosis patients with chronic infections due to pseudomonas aeruginosa
Protocol: TR02-106
Sponsor: GILEAD: http://www.gilead.com/
CRO: i3research: http://www.i3global.com/Businesses/i3Research/

PORT CF: Cystic Fibrosis Patient Registry
Sponsor: CFFoundation: http://cff.org/

PAH Queri
Protocol: CHRC 015
Sponsor:ACTELION: http://www.actelion.com
CRO : MDPrimer Inc.: www.mdprimer.com

Global Clincal Research MGMT.: www.gcrmweb.com

Florida Sleep School http: www.flsleepschool.com

Current CFPG CLIINICAL RESEARCH TRIALS

1. Title:
   A Prospective, Randomized, Open Label, Multicenter, Pilot Study to Evaluate the ROX Anastomotic Coupler System (ACS) in Patients with Chronic Obstructive Pulmonary Disease
   Description:
   Chronic Obstructive Pulmonary Disease (COPD) is a chronic disease that leads to irreversible changes in the lung structure, but also to systemic changes in the body that can influence the severity of the disease. The irreversible changes to the lungs can be seen in limitations to the pulmonary function. The purpose of this clinical investigation is to evaluate the performance and efficacy of the ROX percutaneous Anastomotic Coupler System.
   Link: http://www.clinicaltrials.gov
   


2. Title:
   RESPIRE Registry - Registry to Prospectively Evaluate Use of Ventavis in Patients with Pulmonary Arterial Hypertension
   Description:
   The Ventavis® (iloprost) Registry is a multicenter, observational, U.S.-based study that longitudinally follows patients with pulmonary arterial hypertension (PAH) who have been receiving therapy with Ventavis® for at least 3 months. Patients diagnosed with WHO Group I PAH who are on a stable regimen of commercial Ventavis® will be followed for a maximum of 2 years from the time of enrollment. Data will be collected via patient interview and review of the medical record. Quarterly data collection will include capture of medications and Ventavis® adherence data.
   Link: http://www.clinicaltrials.gov
   


3. Title:
   A Phase IIIb, Multicenter, Open-label Study of Patients with Pulmonary Arterial Hypertension Treated with Iloprost (Inhalation) Evaluating Safety and Inhalation Times when Converting from Power Disc-6 to Power Disc-15 with the I-Neb® AAD®.
   Description:
   Commercial iloprost inhalation solution delivered using the Power Disc-15 with the I-Neb® Adaptive Aerosol Delivery (AAD®) system administered 6 to 9 times per day
   Link: http://www.clinicaltrials.gov


4. Title:
   One Year Study – Study No. AC-063A406
   A multicenter, retrospective study of patients with pulmonary arterial hypertension receiving inhaled iloprost for ≥ year
   Description:
   The Ventavis® (iloprost) Registry is a multicenter, observational, U.S.-based study that longitudinally follows patients with pulmonary arterial hypertension (PAH) who have been receiving therapy with Ventavis® for at least 3 months. Patients diagnosed with WHO Group I PAH who are on a stable regimen of commercial Ventavis® will be followed for a maximum of 2 years from the time of enrollment. Data will be collected via patient interview and review of the medical record. Quarterly data collection will include capture of medications and Ventavis® adherence data.
   Link: http://www.clinicaltrials.gov
   


5. Title:
   A randomized, double-blind, placebo-controlled parallel group study to investigate the safety and efficacy of two doses of tiotropium bromide (2.5 ug and 5.0 ug) administered once daily via the Respimat® device for 12 weeks in patients with Cystic Fibrosis
   Description:
   This study evaluates the effects of 12-week treatment with two doses of tiotropium bromide (2.5 mcg q.d. and 5 mcg q.d.) compared to placebo administered via the Respimat device on lung function in patients with Cystic Fibrosis. The selection of the optimal dose will be based on bronchodilator efficacy, safety evaluations and pharmacokinetic evaluations
   Link: http://www.clinicaltrials.gov